Please login to the form below

Not currently logged in
Email:
Password:

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

This follows prior approval from cost-effective watchdog NICE, which green-lit Keytruda for use in more than 3, 000 non-small cell lung cancer (NSCLC) patients. ... Meindert Boysen, director, NICE Centre for Health Technology Evaluation. “The committee

Latest news

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    In combination with chemotherapy, the anti-PD-1 therapy has been approved as a first-line medicine for those with metastatic squamous non-small cell lung cancer (NSCLC). ... Keytruda provides a foundation for the treatment of lung cancer in Europe, and

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    Celgene picked up the first of these last October when Abraxane was cleared alongside Merck &Co/MSD’s Keytruda (pembrolizumab) for frontline metastatic squamous non-small cell lung cancer. ... for a breast cancer indication – and in September, the

  • Tecentriq combo gains European NSCLC approval Tecentriq combo gains European NSCLC approval

    In combination with chemotherapy and Roche’s older cancer treatment Avastin, Tecentriq can now treat those with EGFR mutant, or ALK-positive metastatic non-squamous non-small cell lung cancer (NSCLC). ... Today’s announcement makes the combination of

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    cancer therapy Herceptin (trastuzumab) offset by gains of 14% in the US and 10% elsewhere. ... for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... The availability of combination therapy is a huge leap forward in improving the prognosis of patients with non-squamous non-small cell lung cancer.”.

More from news
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics